IMS Solutions has raised $1.5M in seed funding to push its adrenal cancer diagnostic toward the clinic. The round was backed by Midlands Mindforge, SFC Capital, the UK Innovation & Science Seed Fund (UKI2S), NG Bio and the British Business Bank.
The company, also known as Intelligent Mass Spec Solutions, is developing a non-invasive test that analyzes a urine sample using high-throughput mass spectrometry and machine learning to identify steroid signatures linked to Adrenocortical Carcinoma, the aim being to help clinicians tell malignant adrenal tumors from benign ones and decide who actually needs surgery. The work builds on clinical data from what the company describes as the world's largest prospective study of ACC, which found a distinctive chemical signature in patients' urine.


















